

Case-Finding List (Effective for Cases DX 2010 and forward)

ICD-9-CM Codes	Diagnosis (in preferred ICD-O-3 terminology)
140.0 - 208.9	Malignant neoplasms (Except 173.0-173.9)
209.00 – 209.29 (New)	Neuroendocrine tumors
209.30 (New)	Malignant poorly differentiated neuroendocrine carcinoma, any site <i>Reportable inclusion terms:</i> <i>High grade neuroendocrine carcinoma, any site</i> <i>Malignant poorly differentiated neuroendocrine tumor NOS</i>
209.31 – 209.36 (New)	Merkel cell carcinoma Note: Effective date 10/1/09
209.70 – 209.79 (New)	Secondary neuroendocrine tumors Note: Effective date 10/1/09 <i>Reportable inclusion terms:</i> <i>Secondary carcinoid tumors</i> Note: All neuroendocrine or carcinoid tumors specified as secondary are malignant
225.0 - 225.9	Benign Brain and Other Parts of Nervous System
227.3 & 227.4	Benign Pituitary Gland and Craniopharyngeal duct (227.3), Pineal Gland (227.4)
227.9 (New)	Benign neoplasm; endocrine gland, site unspecified
228.02 (New)	Hemangioma; of intracranial structures <i>Reportable inclusion terms:</i> <i>Angioma NOS, Cavernous nevus, Glomus tumor, Hemangioma (benign)</i>
228.1 (New)	Lymphangioma, any site
230.0 - 234.9	Carcinoma in situ (Except 232.0 – 232.9 and 233.1)
236.0 (New)	Endometrial stroma, low grade (8931/1) <i>Reportable inclusion terms:</i> <i>Stromal endometriosis (8931/3 per ICD-O-3</i> <i>Stromal myosis (endolymphatic) (8931/3 per ICD-O-3)</i> <i>Stromatosis, endometrial (8931/3 per ICD-O-3)</i>
237.0, 237.1, 237.5, 237.6, 237.70, 237.71, 237.72, 237.9	Neoplasm of Uncertain Behavior Endocrine Gland and Nervous System – Includes Pineal Gland, Brain, and Spinal Cord, Meninges and Neurofibromatosis
238.4	Polycythemia vera (9950/3)
238.6	Solitary plasmacytoma (9731/3) Extramedullary plasmacytoma (9734/3)
238.7 (New)	Other lymphatic and hematopoietic tissues Note: This code was expanded 10/2006. It is now a subcategory and is no longer valid for use for coding purposes. It should be included in extract programs for quality control purposes.
238.71	Essential Thrombocythemia (9962/3) Essential Hemorrhagic Thrombocythemia Essential Thrombocytosis Idiopathic (Hemorrhagic) Thrombocythemia Primary Thrombocytosis
238.72	Refractory anemia (RA) (9980/3) Refractory anemia with ringed sideroblasts (RARS) (9982/3) Refractory cytopenia with multilineage dysplasia (RCMD) (9985/3) Refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS)
238.73	Refractory anemia with excess blasts-1 (RAEB-1) (9983/3) Refractory anemia with excess blasts-2 (RAEB-2) (9983/3)
238.74	Myelodysplastic syndrome with 5q deletion (9986/3) 5q minus syndrome NOS Chronic myeloproliferative disease (9960/3) Myelosclerosis with myeloid metaplasia (9961/3) Refractory cytopenia with multilineage dysplasia (9985/3) Therapy-related myelodysplastic syndrome (9987/3)
238.75	Myelodysplastic syndrome, unspecified (9989/3)
238.76	Myelofibrosis with myeloid metaplasia (9961/3) Agnogenic myeloid metaplasia Idiopathic myelofibrosis (chronic) Myelosclerosis with myeloid metaplasia Primary myelofibrosis
238.77 (New)	Polymorphic Post-Transplant Lymphoproliferative Disorder (9971/3)

	Post-Transplant Lymphoproliferative Disorder (9987/3)
238.79	Lymphoproliferative disease (chronic) NOS (9970/1) Megakaryocytic myelosclerosis (9961/3) Myeloproliferative disease (chronic) J5511 NOS (9960/3) Panmyelosis (acute) (9931/3)
239.6 (New)	Neoplasms of unspecified nature, brain
239.7 (New)	Neoplasms of unspecified nature; endocrine glands and other parts of nervous system
239.81 – 239.89 (New)	Neoplasms of unspecified nature; other specified sites Note: Effective date 10/1/09
273.2	Gamma heavy chain disease; Franklin's disease (9762/3)
273.3	Waldenstrom's macroglobulinemia (9761/3)
288.3	Hypereosinophilic syndrome (9964/3)
288.4 (New)	Hemophagocytic syndromes <i>Reportable inclusion terms:</i> <i>Histiocytic syndromes (9751/3)</i> Note: Hemophagocytic lymphohistiocytosis (also known as hemophagocytic syndrome) can be caused by or associated with a number of conditions, one of which is EBV+ T-cell lymphoproliferative disease of childhood (9724/3)
289.83	Acute myelofibrosis (9931/3)
758.0 (New)	Myeloid leukemia associated with Down Syndrome (9898)
795.06	Papanicolaou smear of cervix with cytologic evidence of malignancy (without histologic confirmation) (positive Pap smear)
795.16 (New)	Papanicolaou smear of vagina with cytologic evidence of malignancy
796.76 (New)	Papanicolaou smear of anus with cytologic evidence of malignancy
V10.0 - V10.9	Personal history of malignancy (review these for recurrences, subsequent primaries, and/or subsequent treatment)
V10.91 (New)	Personal history of malignant neuroendocrine tumor, carcinoid tumor, merkel cell carcinoma Note: Effective date 10/1/09. Screen for recurrences, subsequent primaries, and/or subsequent treatment
V12.41 (New)	Personal history of benign neoplasm of the brain.
V58.0	Admission for radiotherapy
V58.11 – V58.12	Admission for chemotherapy
V66.1	Convalescence following radiotherapy
V66.2	Convalescence following chemotherapy
V67.1	Radiation therapy follow-up
V67.2	Chemotherapy follow-up
V76.0 - V76.9	Special screening for malignant neoplasm
V86.0	Estrogen receptor positive status [ER+] (new code)
V86.1	Estrogen receptor negative status [ER-] (new code)

Reference: http://training.seer.cancer.gov/module_icd3/icd_o_3_lists.html